MedTrace Logo

Exploratory Clinical Study to Evaluate the Optimal Dosage of Mosapride and Probiotics in Irritable Bowel Syndrome Without Predominant Diarrhea

NCT01505777 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 280

Last updated 2013-04-05

No results posted yet for this study

Summary

The purpose of this study is to Evaluate the Optimal Dosage of Mosapride (Medirac) and Probitics in Irritable Bowel Syndrome Without Predominant Diarrhea.

Conditions

  • Irritable Bowel Syndrome Without Diarrhea

Interventions

DRUG

Probiotics (Medirac)

10/mosapride 10mg three times a day, P.O. 4week

DRUG

Probiotics (Medirac)

15/mosapride 10mg three times a day, P.O. 4week

DRUG

Probiotics (Medirac)

15/mosapride 15mg three times a day, P.O. 4week

DRUG

Probiotics (Medirac)

30/mosapride 15mg three times a day, P.O. 4week

DRUG

Probiotics (Medirac) placebo/mosapride placebo

three times a day, P.O. 4week

Sponsors & Collaborators

  • Hanmi Pharmaceutical Company Limited

    lead INDUSTRY

Principal Investigators

  • Hyo Jin Park, M.D., Ph.D. · Gangnam Severance Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2012-06-30
Completion
2012-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01505777 on ClinicalTrials.gov